SOME COMPLEXITY IN PDL1 DIAGNOSTICS FOR NSCLC
Nivolumab:
BMS
Pembrolizum
ab: Merck
Atezolizumab:
Roche
Durvalumab:
AstraZeneca
Avelumab:
Pfizer
Ab Clone
28-8
SP263
22C3
SP142
SP263
73-10
Diagnostic
Partner
Dako
Ventana
Dako
Ventana
Ventana
Dako
Scoring
Method
% of PD-L1–expressing
tumour cells
% of PD-L1–
expressing
tumour cells
% of PD-L1–
expressing
tumour cells
or immune
cells
% of PD-L1–
expressing
tumour cells
% of PD-L1–
expressing
tumour cells
PD-L1
Thresholds
TC ≥1% (pos), ≥5%
(strong), or ≥10%
TC ≥1% (pos)
TC ≥50%
(strong)
TC /
IC 3(+)
TC /
IC 2(+)
TC /
IC 1(+
)
TC /
IC 0(−)
TC
PD-L1(+): ≥
25%
TBC, TC
between all
>1% and 25%
with moderate
or high
intensity
